A carregar...
Publicação
Agonistas do recetor do GLP1 na prevenção de acidente vascular cerebral em doentes com diabetes mellitus
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1017.28 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
Nesta tese será abordado o efeito dos agonistas do recetor do glucagon-like peptide-1 (GLP1) na prevenção de ocorrência de acidentes vasculares cerebrais (AVC) em doentes com diagnóstico de Diabetes Mellitus tipo 2. A Diabetes Mellitus é uma doença crónica altamente prevalente a nível mundial, estando associada ao envelhecimento vascular prematuro, o que, por sua vez, é um fator de risco considerável para a ocorrência de AVC. Os agonistas do recetor do GLP1 são uma classe de fármacos que tem sido utilizada para o tratamento da Diabetes Mellitus e em ensaios clínicos surgiu a hipótese de os mesmos serem benéficos a nível cardiovascular. O principal objetivo desta revisão narrativa prende-se na identificação, análise e sistematização da evidência existente relativa ao papel dos agonistas do recetor do GLP1 na redução do risco de ocorrência de AVC em doentes diabéticos. Para a elaboração desta revisão narrativa foi utilizado o motor de busca PubMed. Realizou-se uma seleção dos artigos mais relevantes e procedeu-se à análise dos mesmos. Os resultados obtidos sugerem um papel protetor a nível cerebrovascular dos agonistas do recetor do GLP1 em prevenção secundária, apontando para uma redução significativa na incidência de AVC em doentes com diagnóstico de Diabetes Mellitus tipo 2 e que realizam terapêutica com medicamentos pertencentes a esta classe farmacológica.
This thesis will address the effect of glucagon-like peptide-1 (GLP1) receptor agonists in preventing the occurrence of cerebrovascular accidents (CVA) in patients diagnosed with type 2 Diabetes Mellitus. Diabetes Mellitus is a highly prevalent chronic disease worldwide, associated with premature vascular aging, which in turn is a considerable risk factor for the occurrence of stroke. GLP1 receptor agonists are a class of drugs that have been used to treat Diabetes Mellitus and in clinical trials has emerged the hypothesis that they are beneficial at a cardiovascular level. The main objective of this thesis is to identify, analyze and systematize the existing evidence regarding the role of GLP1 receptor agonists in reducing the risk of stroke in patients with type 2 Diabetes Mellitus. To prepare this thesis, the search engine PubMed was used, and then the most relevant articles were selected and analyzed. The results obtained suggest a protective role at the cerebrovascular level of GLP1 receptor agonists in secondary prevention, pointing to a significant reduction in the incidence of stroke in patients diagnosed with type 2 Diabetes Mellitus and undergoing therapy with medications belonging to this pharmacological class.
This thesis will address the effect of glucagon-like peptide-1 (GLP1) receptor agonists in preventing the occurrence of cerebrovascular accidents (CVA) in patients diagnosed with type 2 Diabetes Mellitus. Diabetes Mellitus is a highly prevalent chronic disease worldwide, associated with premature vascular aging, which in turn is a considerable risk factor for the occurrence of stroke. GLP1 receptor agonists are a class of drugs that have been used to treat Diabetes Mellitus and in clinical trials has emerged the hypothesis that they are beneficial at a cardiovascular level. The main objective of this thesis is to identify, analyze and systematize the existing evidence regarding the role of GLP1 receptor agonists in reducing the risk of stroke in patients with type 2 Diabetes Mellitus. To prepare this thesis, the search engine PubMed was used, and then the most relevant articles were selected and analyzed. The results obtained suggest a protective role at the cerebrovascular level of GLP1 receptor agonists in secondary prevention, pointing to a significant reduction in the incidence of stroke in patients diagnosed with type 2 Diabetes Mellitus and undergoing therapy with medications belonging to this pharmacological class.
Descrição
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2024
Palavras-chave
Acidente vascular cerebral Diabetes mellitus Agonistas do recetor do GLP1 Prevenção